Related Experiment Video
Updated: Sep 26, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Systemic therapy for advanced pancreatic cancer
Basil F El-Rayes1, Philip A Philip
1Division of Haematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Abstract:
Death from pancreatic cancer remains high with few long-term survivors. Systemic chemotherapy with 5-fluorouracil-based combinations had minimal impact on natural history of this disease. Several new agents with activity against pancreatic cancer have been identified over the past decade. Gemcitabine has modest activity in this disease. Combination chemotherapy trials incorporating gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, docetaxel or irinotecan show improved outcomes in objective response rates and survival that need to be confirmed in prospectively randomized studies. Advancement in the understanding of the biology of pancreatic cancer has helped identify several molecular targets for the development of novel therapies. Ongoing and future treatment regimens for pancreatic cancer will incorporate traditional cytotoxic drugs and novel targeted therapies.
Insights
Pancreatic cancer survival remains poor, with limited success from 5-fluorouracil chemotherapy. New combination therapies show promise, but require further randomized trials for confirmation.
Area of Science:
- Oncology
- Medical Research
Background:
- Pancreatic cancer has a high mortality rate with limited long-term survival.
- Traditional 5-fluorouracil chemotherapy has shown minimal impact on patient outcomes.
Purpose of the Study:
- To review the efficacy of novel chemotherapeutic agents and combination therapies for pancreatic cancer.
- To highlight advancements in understanding pancreatic cancer biology for targeted therapy development.
Main Methods:
- Review of recent studies on pancreatic cancer treatment.
- Analysis of combination chemotherapy trials involving gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, docetaxel, and irinotecan.
Main Results:
- Gemcitabine demonstrates modest activity in pancreatic cancer.
- Combination chemotherapy regimens show improved objective response rates and survival, warranting further investigation.
- Advances in molecular biology have identified new therapeutic targets.
Conclusions:
- Current and future pancreatic cancer treatment strategies will integrate conventional cytotoxic agents with novel targeted therapies.
- Further randomized studies are essential to validate the benefits of new combination regimens.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Tumor Immunotherapy